The article provides updates on results from various pharmaceutical studies. Genentech Inc.'s Phase III study shows the effectiveness of the combination of chemotherapy and its antibody Avastin for the treatment of ovarian cancer. The SUN 1064 Phase III study on Pfizer Inc.'s Sutent reveals that the drug did not show an improvement when combined with docetaxel in the treatment of breast cancer. Genmab A/S reported positive results of Phase III zalutumumab study on cancer treatment.
Processing Request
No Comments.